S&P 500   4,280.32 (+0.15%)
DOW   33,909.24 (-0.21%)
QQQ   329.61 (+0.34%)
AAPL   174.40 (-0.09%)
MSFT   291.01 (-0.11%)
META   175.14 (+0.17%)
GOOGL   120.26 (+0.59%)
AMZN   142.35 (+0.18%)
TSLA   913.73 (+0.19%)
NVDA   187.69 (+2.37%)
NIO   19.87 (-1.05%)
BABA   90.79 (+1.14%)
AMD   100.66 (+2.43%)
MU   63.10 (+2.40%)
T   18.50 (+0.43%)
CGC   3.78 (-6.90%)
F   16.05 (+0.12%)
GE   79.30 (-0.78%)
DIS   122.51 (-0.24%)
AMC   19.83 (-7.16%)
PYPL   99.02 (-0.40%)
PFE   48.45 (-1.66%)
NFLX   244.94 (+1.57%)
S&P 500   4,280.32 (+0.15%)
DOW   33,909.24 (-0.21%)
QQQ   329.61 (+0.34%)
AAPL   174.40 (-0.09%)
MSFT   291.01 (-0.11%)
META   175.14 (+0.17%)
GOOGL   120.26 (+0.59%)
AMZN   142.35 (+0.18%)
TSLA   913.73 (+0.19%)
NVDA   187.69 (+2.37%)
NIO   19.87 (-1.05%)
BABA   90.79 (+1.14%)
AMD   100.66 (+2.43%)
MU   63.10 (+2.40%)
T   18.50 (+0.43%)
CGC   3.78 (-6.90%)
F   16.05 (+0.12%)
GE   79.30 (-0.78%)
DIS   122.51 (-0.24%)
AMC   19.83 (-7.16%)
PYPL   99.02 (-0.40%)
PFE   48.45 (-1.66%)
NFLX   244.94 (+1.57%)
S&P 500   4,280.32 (+0.15%)
DOW   33,909.24 (-0.21%)
QQQ   329.61 (+0.34%)
AAPL   174.40 (-0.09%)
MSFT   291.01 (-0.11%)
META   175.14 (+0.17%)
GOOGL   120.26 (+0.59%)
AMZN   142.35 (+0.18%)
TSLA   913.73 (+0.19%)
NVDA   187.69 (+2.37%)
NIO   19.87 (-1.05%)
BABA   90.79 (+1.14%)
AMD   100.66 (+2.43%)
MU   63.10 (+2.40%)
T   18.50 (+0.43%)
CGC   3.78 (-6.90%)
F   16.05 (+0.12%)
GE   79.30 (-0.78%)
DIS   122.51 (-0.24%)
AMC   19.83 (-7.16%)
PYPL   99.02 (-0.40%)
PFE   48.45 (-1.66%)
NFLX   244.94 (+1.57%)
S&P 500   4,280.32 (+0.15%)
DOW   33,909.24 (-0.21%)
QQQ   329.61 (+0.34%)
AAPL   174.40 (-0.09%)
MSFT   291.01 (-0.11%)
META   175.14 (+0.17%)
GOOGL   120.26 (+0.59%)
AMZN   142.35 (+0.18%)
TSLA   913.73 (+0.19%)
NVDA   187.69 (+2.37%)
NIO   19.87 (-1.05%)
BABA   90.79 (+1.14%)
AMD   100.66 (+2.43%)
MU   63.10 (+2.40%)
T   18.50 (+0.43%)
CGC   3.78 (-6.90%)
F   16.05 (+0.12%)
GE   79.30 (-0.78%)
DIS   122.51 (-0.24%)
AMC   19.83 (-7.16%)
PYPL   99.02 (-0.40%)
PFE   48.45 (-1.66%)
NFLX   244.94 (+1.57%)
NASDAQ:SVA

Sinovac Biotech - SVA Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$6.47
$6.47
50-Day Range
$6.47
$6.47
52-Week Range
$5.73
$8.75
Volume
N/A
Average Volume
N/A
Market Capitalization
$643.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
SVA stock logo

About Sinovac Biotech (NASDAQ:SVA) Stock

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

Receive SVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sinovac Biotech and its competitors with MarketBeat's FREE daily newsletter.

SVA Stock News Headlines

SINOVAC Polio Vaccine Prequalified by WHO
See More Headlines

Receive SVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sinovac Biotech and its competitors with MarketBeat's FREE daily newsletter.

SVA Company Calendar

Today
8/18/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SVA
Employees
4,281
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$19.37 billion
Cash Flow
$92.43 per share
Book Value
$139.45 per share

Miscellaneous

Free Float
N/A
Market Cap
$643.77 million
Optionable
Optionable
Beta
37.20














SVA Stock - Frequently Asked Questions

What other stocks do shareholders of Sinovac Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sinovac Biotech investors own include Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), AT&T (T), Tesla (TSLA), VIVUS (VVUS), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Micron Technology (MU) and TherapeuticsMD (TXMD).

What is Sinovac Biotech's stock symbol?

Sinovac Biotech trades on the NASDAQ under the ticker symbol "SVA."

Who are Sinovac Biotech's major shareholders?

Sinovac Biotech's stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.39%), State Street Corp (0.16%), Northern Trust Corp (0.01%), UBS Group AG (0.01%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

What is Sinovac Biotech's stock price today?

One share of SVA stock can currently be purchased for approximately $6.47.

How much money does Sinovac Biotech make?

Sinovac Biotech (NASDAQ:SVA) has a market capitalization of $643.77 million and generates $19.37 billion in revenue each year.

How many employees does Sinovac Biotech have?

The company employs 4,281 workers across the globe.

How can I contact Sinovac Biotech?

Sinovac Biotech's mailing address is NO. 15 ZHI TONG ROAD ZHONGGUANCUN TECH PARK CHANGPING DISTR., BEIJING F4, 102200. The official website for the company is www.sinovac.com. The biopharmaceutical company can be reached via phone at 86-10-5693-1800, via email at ir@sinovac.com, or via fax at 86-10-5693-1800.

This page (NASDAQ:SVA) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.